By rray, 31 October, 2023 Report adverse events to the Vaccine Adverse Event Reporting System https vaers hhs gov index html or 1 800 822 7967
By rray, 31 October, 2023 Contraindication Don t administer to those w hx of severe allergic reaction e g anaphylaxis to any component of the vaccine
By rray, 31 October, 2023 Precaution Delay vaccination for those experiencing moderate or severe acute illness w or w o fever
By rray, 31 October, 2023 Nirsevimab vaccination may be considered for infants born to vaccinated parents in rare circumstances such as the following nbsp Parent might not have mounted an adequate immune response to vaccination e g they have an immunocompromising condition nbsp Pa
By rray, 31 October, 2023 Nirsevimab vaccination in infants is recommended when the infant meets 1 of the following criteria nbsp
By rray, 31 October, 2023 Protection conferred through vaccination of the pregnant pt will likely wane after 3mo However because vaccination at 32 36 wk gestation is recommended only from Sept to Jan in most of the continental U S most infants of pts vaccinated during pregnancy wi
By rray, 31 October, 2023 Discuss the relative advantages and disadvantages of both options w the pregnant pt and consider their preferences when determining whether to vaccinate the pt or administer nirsevimab to the infant
By rray, 31 October, 2023 To prevent RSV associated LRTI in infants either RSVpreF vaccination in pregnant parents at 32 36 wk gestation OR nirsevimab immunization in infants